Track Caribou Biosciences Inc. Common Stock — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Caribou Biosciences Inc. Common Stock CRBU · Stock Open Caribou Biosciences Inc. Common Stock in new tab

0.3619 USD
EPS
-0.98
P/B
0.51
ROE
-93.80
Beta
2.49
Target Price
5.00 USD
Loading chart...
Key Metrics
Earnings dateMarch 4, 2027
EPS-0.98
Book Value0.71
Price to Book0.51
Debt/Equity34.37
% Insiders8.808%
Growth
Revenue Growth-0.27%
Estimates
Forward P/E-0.40
Forward EPS-0.90
Target Mean Price5.00

DCF valuation

Model fair value for Caribou Biosciences Inc. Common Stock (CRBU)
Result
Sign in to run the valuation for CRBU.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
3 analysts · consensus Hold · mean target 5.00 USD (low 1.00, high 13.00) · as of 15 Nov 2026
Low 1.00
Mean 5.00
High 13.00
Price 0.3619
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Caribou Biosciences Inc. Common Stock Logo Caribou Biosciences Inc. Common Stock Analysis (CRBU)

United States Health Care Official Website Stock

Is Caribou Biosciences Inc. Common Stock a good investment? Caribou Biosciences Inc. Common Stock (CRBU) is currently trading at 0.3619 USD. Market analysts have a consensus price target of 5.00 USD. This suggests a potential upside from current levels.

Earnings Schedule: Caribou Biosciences Inc. Common Stock is expected to release its next earnings report on March 4, 2027. The market consensus estimate for Forward EPS is -0.90.

Investor FAQ

Does Caribou Biosciences Inc. Common Stock pay a dividend?

No, it does not currently pay a dividend.

What asset class is Caribou Biosciences Inc. Common Stock?

Caribou Biosciences Inc. Common Stock is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be March 4, 2027. The company currently has a trailing EPS of -0.98.

Company Profile

Caribou Biosciences, Inc. operates as a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company. It offers a genome-editing platform based on novel CRISPR hybrid RNA-DNA genome-editing technology that enables precise genome editing of allogeneic cell therapies. The company develops Vispacabtagene Regedleucel, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.

Exchange Ticker
NMS (United States) CRBU
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion